GlassScriptPhysician profile
Amishi S Murthy
NPI 1699978791
$9,142.60
in general payments reported to CMS, 2019-2025
33 companies · $1,683 in 2025
The $1,683 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $818 · 2020: $213 · 2021: $948 · 2022: $1,335 · 2023: $1,869 · 2024: $2,277 · 2025: $1,683.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,732 · Education: $82.09 · Consulting Fee: $14.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,732.27 |
| Education | $82.09 |
| Consulting Fee | $14.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,118.45 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Genzyme Corporation | $1,123.76 | 2019-2025 | |
| Glaxosmithkline, LLC. | $935.79 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Regeneron Healthcare Solutions, INC. | $767.25 | 2021-2025 | Dupixent |
| Csl Behring | $605.54 | 2021-2025 | Haegarda, Andembry, Kcentra |
| Kaleo, INC. | $365.07 | 2019-2024 | Auvi-Q |
| Hospira, INC. | $315.49 | 2019-2025 | |
| Genentech USA, INC. | $263.96 | 2019-2025 | Xolair |
| Biocryst US Sales Co., LLC | $250.97 | 2021-2025 | Orladeyo |
| Alk-Abello, INC | $250.66 | 2020-2025 | Ragwitek, Grastek, Odactra |
| Octapharma USA, INC. | $233.80 | 2021-2024 | Panzyga |
| Covis Pharma Gmbh | $208.91 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $185.60 | 2019-2025 | |
| Pfizer INC. | $182.90 | 2019-2022 | |
| Hikma Pharmaceuticals USA | $178.32 | 2022-2025 | Ryaltris |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ars Pharmaceuticals Operations, INC. | $172.32 | 2025 | Neffy |
| Pharming Healthcare, INC. | $141.19 | 2023-2024 | Ruconest |
| Teva Pharmaceuticals USA, INC. | $110.43 | 2019-2022 | |
| Amgen INC. | $104.46 | 2022-2025 | Tezspire |
| Optinose US, INC. | $97.75 | 2019-2022 | |
| Leo Pharma INC. | $79.41 | 2022-2024 | Adbry |
| Tersera Therapeutics LLC | $62.94 | 2023 | Quzyttir |
| Takeda Pharmaceuticals U.S.A., INC. | $59.32 | 2021-2023 | Takhzyro |
| Kedrion Biopharma, INC. | $57.69 | 2024-2025 | Gammaked, Kedrab, Koate |
| Nestle Healthcare Nutrition INC. | $43.08 | 2021-2023 | |
| Grifols USA, LLC | $42.31 | 2023-2024 | Xembify |
| Bio Products Laboratory USA, INC. | $40.27 | 2023 | Gammaplex, Coagadex |
| Aimmune Therapeutics, INC. | $36.30 | 2021-2022 | |
| Phadia US INC. | $33.57 | 2024 | Immunocap |
| Shire North American Group INC | $24.61 | 2019 | |
| Blueprint Medicines Corporation | $18.36 | 2023 | Ayvakit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.37 | 2021 | |
| Adma Biomanufacturing LLC | $14.75 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amishi Murthy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.